Expanding the Stroke Treatment Window: HOPE Trial Findings
A landmark study in JAMA — the HOPE randomized clinical trial — shows that intravenous alteplase can be effective up to 24 hours after stroke onset, when patients are selected by advanced imaging (CT perfusion).
Highlights:
- Functional benefit: 40% of patients receiving alteplase achieved independence at 90 days vs 26% under standard care.
- Safety: Slightly higher risk of symptomatic intracranial hemorrhage (3.8% vs 0.5%) but no increase in mortality.
Why imaging matters: Perfusion imaging was key to identifying salvageable brain tissue beyond conventional time limits—underscoring the role of AI-enabled image analysis in extending treatment opportunities.
Global impact: Extending the treatment window could especially benefit patients in remote or resource-limited settings where thrombectomy isn't readily available.
Why this matters to us: At PurpleAI, we're committed to advancing AI-powered stroke imaging to help clinicians act quickly and accurately. Findings like HOPE highlight how imaging-driven decision-making can reshape stroke care worldwide.
📖 Read the full study in JAMA: (https://lnkd.in/gXJrWYbt)
#AcuteIschemicStroke #StrokeTreatment #StrokeAwareness #MedicalImaging #CTPerfusion #AIinHealthcare #AIMedicalImaging #DigitalHealth #ClinicalTrials #HOPETrial #EvidenceBasedMedicine #Neurology #HealthcareInnovation #GlobalHealth #MedTech